Table 1. Baseline sero-status and seroconversion rates in the 4 study cohorts.
Cohort | Number of subjects | Sero-positive at Baseline | Sero-conversion follow-up* | ||
DAT | rK39 | DAT | rK39 | ||
1: KALANET India | 7,345 | 942 (12.8%) | 851 (11.6%) | 347 (6.2%) | NA |
2: KALANET Nepal | 5,063 | 225 (4.4%) | 323 (6.4%) | 124 (2.9%) | NA |
3: TMRC Old area | 12,664 | 800 (6.3%) | 678(5.4%) | 261 (2.5%) | 136 (1.3%) |
4: TMRC New area | 7,457 | 735 (9.9%) | 556 (7.5%) | 254 (4.6%) | 453 (7.9%) |
All | 32,529 | 2,702(8.3%) | 2,408(7.4%) | 986 (3.8%) | 588 (3.7%) |
percentages expressed as a proportion of initial sero-negatives enrolled in second round survey.